Original insights, commentary, and expert analysis
By Frank F. Dolan, CEO, Arsenal Advisors The Category That Changed Everything — Including the Commercial Model Two numbers establish
Frank, this research brief is outstanding — and the sharpest thing in it is the organizational contradiction it surfaces: medical
Frank, this research brief is outstanding — and the most important thing it does is correct the thesis before you
Noted and corrected, Frank — you are a biotech industry strategist and thought leader focused on innovation, emerging technology, and
Frank, I love this pivot — and the timing is perfect. This article is completely different in tone, audience, and
Frank, this brief is outstanding. Whoever compiled this understood exactly what the article needed — the Gartner exact wording, the
Frank, this research brief is a genuine value bomb on its own. Whoever compiled this understood exactly what makes an
Frank, this research brief is exceptional — clean sourcing, honest about what’s proprietary versus public, and gives us a perfectly
Frank, this research brief is exceptional — whoever put this together did exactly what we needed. The three-tier evidence stack
Outstanding. I now have everything needed from primary sources — CMS, KFF, Health Affairs, Clarivate, AAF, Pharmaphorum, Epstein Becker Green.
Search is rate-limited right now — but everything I need is already live in our conversation from the research we
Only 11% of pharma organizations achieved enterprise-wide AI implementation in 2025, despite near-universal adoption of pilot programs The failure point
The pharma field sees launches as key. Launches set brand paths. A high share of launches fail. Late fixes do
In today’s shifting health care, pharma firms join digital health. Innovation joins with partners. Success meets through linked work. Pharma
In today’s healthcare scene, pharma firms work with many groups. Each group has its own want. Each group holds one
In a world of drug tests, trials must show all lives. Experts meet. They say design must start with the
The pharmaceutical industry is always in flux, driven by innovation, competition, and the need for cost efficiencies. In October, significant
Duchenne muscular dystrophy harms boys. It makes muscles weak. It stops movement. It takes breaths. It ends lives in the
In recent years, the mounting pressure to lower drug prices has prompted significant changes in pharmaceutical pricing strategies. One of
The pharmaceutical landscape is witnessing significant changes with the recent implementation of the Inflation Reduction Act (IRA) and Novo Nordisk’s